Multi-chemothermoimmunotherapy for human colon adenocarcinoma in vitro.
Effective adjunctive therapies for colorectal carcinoma are clearly needed. We evaluated the cytotoxic responses in vitro of human colon carcinoma cell lines to combined modalities: 5-fluorouracil/leucovorin (5-FU/LV), carboplatin (CP), tumor necrosis factor (TNF) and hyperthermia (HTX). Cytotoxicity was evaluated in a cell proliferation assay using crystal violet staining. 5-FU/LV was administered 2-3 days before TNF and CP, followed 1 h later by HTX. These cell lines were relatively resistant to HTX alone (42 degrees C for 2 h), but were heterogeneous in their responses to various doses of the other single agents. This heterogeneity was also evident for combined modalities: the HCT-15 cell line exhibited significant supra-additivity for selected doses of CP, TNF and 5-FU/LV, which was further enhanced by hyperthermia. In contrast, the HT-29 cell line did not demonstrate a strong pattern for supra-additivity, whereas the DLD-1 cell line had an intermediate response. Thus, our results suggest one approach to develop effective and dose-sparing multimodality therapeutic regimens for colon adenocarcinoma.
Department of Tumor Biology, University of Texas, Houston, USA.
J
J
Klostergaard
M E
ME
Leroux
H A
HA
Hsu
B P
BP
Hsi
Z H
ZH
Siddik
L L
LL
Danhauser
S P
SP
Tomasovi
D000230:Adenocarcinoma / Q000188:drug therapy / Q000628:therapy*; D000704:Analysis of Variance; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016190:Carboplatin / Q000008:administration & dosage*; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000628:therapy*; D003131:Combined Modality Therapy; D005334:Fever; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D002955:Leucovorin / Q000008:administration & dosage*; D016014:Linear Models; D016015:Logistic Models; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage*
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D014409:Tumor Necrosis Factor-alpha; D016190:Carboplatin; D002955:Leucovorin; D005472:Fluorouracil